TerminatedNot Applicable

Advanced Reperfusion Strategies for Refractory Cardiac Arrest

Stopped: For early efficacy

United States30 participantsStarted 2019-08-09

Plain-language summary

This is a Phase II, single center (Under the Center for Resuscitation Medicine at the University of Minnesota Medical School), partially blinded, prospective, intention to treat, safety and efficacy clinical trial, randomizing adult patients (18-75 years old) with refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/VT) out-of hospital cardiac arrest (OHCA) who are transferred by emergency medical services (EMS) with ongoing mechanical cardiopulmonary resuscitation (CPR) or who are resuscitated to receive one of the 2 local standards of care practiced in our community: 1) Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation or 2) Standard Advanced Cardiac Life Support (ACLS) Resuscitation

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults (presumed or known to be aged 18-75 years, inclusive), * An initial documented OHCA rhythm of VF/VT, * No ROSC following 3 defibrillation shocks, * Body morphology able to accommodate a Lund University Cardiac Arrest System (LUCAS™) automated CPR device, and * Estimated transfer time from the scene to the ED or CCL of \< 30 minutes. Exclusion Criteria: * Age \< 18 years old or \> 75 years old; * Non-shockable initial OHCA rhythm (pulseless electrical activity \[PEA\] or asystole); * Valid do-not-attempt-resuscitation orders (DNAR); * Blunt, penetrating, or burn-related injury, drowning, electrocution or known overdose; * Known prisoners; * Known pregnancy; * Nursing home residents; * Unavailability of the cardiac catheterization laboratory. * Severe concomitant illness that drastically shortens life expectancy or increases risk of the procedure; * Absolute contraindications to emergent coronary angiography including known anaphylactic reaction to angiographic contrast media and/or active gastrointestinal or internal bleeding

What they're measuring

Survival

Timeframe: Approximately 25 days

Trial details

NCT IDNCT03880565

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-10-09

Results submitted2021-09-20